Yes, modestly, and they are legitimate, well-studied options, especially for women who cannot or choose not to take hormones.

Low-dose paroxetine is the one FDA-approved SSRI for hot flashes. Escitalopram and venlafaxine both showed real, statistically significant reductions in randomized trials. Gabapentin showed a meaningful reduction and is often dosed at night because it causes sedation, which some women use to their advantage for sleep. All of these have smaller effects than standard-dose estrogen, and dosing for hot flashes is generally lower than dosing used for depression.

What to know about this answer

There is little dispute that these medications work better than placebo. The honest caveat, stated by the reviewing authors themselves, is that their effects are meaningfully smaller than estrogen's, so they are best framed as the right choice for specific women rather than a general first-line substitute for hormone therapy.

What the research shows, and which source each finding rests on

Escitalopram 10-20 mg reduced hot flashes by 4.60 versus 3.20 fewer per day compared with placebo at 8 weeks; 55 percent versus 36 percent of women achieved at least a 50 percent reduction

B[1]

In a head-to-head trial, venlafaxine 75 mg XR versus low-dose estradiol 0.5 mg: vasomotor symptom frequency reduction at 8 weeks was 52.9 percent for estradiol, 47.6 percent for venlafaxine, and 28.6 percent for placebo

B[2]

Gabapentin 900 mg/day produced a 45 percent reduction in hot flash frequency versus 29 percent for placebo at 12 weeks (p = 0.02); sedation is the common tradeoff, which clinicians exploit by dosing at night

B[3]

Paroxetine 7.5 mg, the one FDA-approved SSRI for hot flashes, modestly but significantly reduced vasomotor symptom frequency versus placebo at weeks 4 and 12 in its two phase 3 trials (n = 1,184 total), with benefit persisting at 24 weeks

B[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Modest but real, sized correctly by the field's own review

Nelson and colleagues' class-level meta-analysis

SSRIs and SNRIs reduce daily hot flashes by about 1.13 more than placebo and gabapentin by about 2.05 more, both real effects, but the authors' own summary states that effects are less than for estrogen and that these options may be most useful for highly symptomatic women who cannot take estrogen, rather than optimal choices for most women.

B[3]

What would settle it: This is already reasonably well established at the class level; individual choice mainly comes down to a woman's specific contraindications, side-effect tolerance, and whether a sleep or mood benefit is also wanted.

What is really going on here

  1. Is my antidepressant dose set for hot flashes or for depression? Vasomotor symptom dosing (paroxetine 7.5 mg, venlafaxine 75 mg XR) is lower than depression dosing; higher is not better for this indication.

Questions for your doctor

  1. Is the dose you're prescribing calibrated for hot flashes specifically, not depression dosing?
  2. Am I a candidate for hormone therapy, and if not, why is this the recommended alternative for me?
  3. What side effects should I expect, and would taking it at night help, for gabapentin?
  4. How long should I try it before we know if it's working?

Questions with no answer yet

Since these drugs' effects on hot flashes are meaningfully smaller than estrogen's, is there a way to predict in advance which specific women will get a large versus a minimal benefit, rather than a uniform modest effect across everyone?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The class-level meta-analysis reports average effect sizes without identifying predictors of individual response. These are framed as best for highly symptomatic women who cannot take estrogen, without a validated way to select responders in advance.

What would test it: A study identifying biological or clinical predictors of strong versus weak response to these nonhormonal drugs, to enable more individualized prescribing.

Does gabapentin's sedative side effect, which clinicians deliberately use for nighttime dosing, mean its apparent hot flash benefit is partly really a sleep benefit rather than a direct effect on the hot flash mechanism itself?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Gabapentin's pivotal trial measured hot flash frequency reduction directly, while clinicians separately dose it at night specifically to exploit its sedative effect, without a study separating a direct anti-flash effect from an indirect sleep-mediated one.

What would test it: A trial using objective monitoring to see whether gabapentin reduces the number of hot flashes themselves versus mainly reducing wakefulness during them.

If dosing for hot flashes is deliberately lower than dosing for depression or anxiety, does that mean these drugs are working through a different mechanism for hot flashes than for mood, or simply that a smaller dose is sufficient for both?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Vasomotor symptom dosing is established as lower than mood dosing for the same drugs as a clinical fact, without addressing whether this reflects a distinct mechanism of action for hot flashes.

What would test it: Dose-response and mechanistic studies comparing how these drugs act on thermoregulatory pathways versus mood pathways at different doses.

Sources

  1. 1.Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.Freeman EW et al., JAMA 2011 · Randomised trial
  2. 2.Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.Joffe H et al., JAMA Intern Med 2014 · Randomised trial
  3. 3.Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.Guttuso T et al., Obstet Gynecol 2003 · Randomised trial
  4. 4.Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.Simon JA et al., Menopause 2013 · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides